What prices are associated with Steven Pieper’s Xeris Biopharma (XERS) share acquisitions?

The reported acquisitions list per-share prices of $4.09 for 27,891 common shares and $5.93 for 14,036 common shares. These prices appear in the common stock transaction lines tied to derivative exercises, indicating the share-level amounts recorded when options were converted into common stock on March 5, 2026.

Xeris Biopharma (XERS) officer exercises options, lifts share holdings

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Xeris Biopharma Holdings reported that officer Steven Pieper exercised stock options and acquired common shares. On March 5, 2026, he converted options into 27,891 common shares at $4.09 per share and 14,036 common shares at $5.93 per share through derivative exercises.

These options were originally granted on January 31, 2018 and December 10, 2020 under company stock option plans with vesting tied to continued employment. Following the transactions, he directly owned up to 1,408,940 common shares.

Insider Trade Summary

41,927 shares exercised/converted

Mixed 4 txns

Insider Pieper Steven

Role See Remarks

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	27,891	$0.00	--
Exercise	Stock Option (Right to Buy)	14,036	$0.00	--
Exercise	Common Stock	27,891	$4.09	$114K
Exercise	Common Stock	14,036	$5.93	$83K

Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 1,394,904 shares (Direct)

Footnotes (1)

The reporting person received the stock options on December 10, 2020 pursuant to an award under the Company's 2018 Stock Option/Stock Issuance Plan. 50% of the options vested on the first anniversary of the vesting commencement date, and the remaining 50% of options vested on the second anniversary of the vesting commencement date, in each case subject to continued employment through such vesting date. The reporting person received the stock options on January 31, 2018 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

03/05/2026 - 07:18 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pieper Steven

(Last)

(First)

(Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO

60607

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/05/2026		M		27,891	A	$4.09	1,394,904	D
Common Stock	03/05/2026		M		14,036	A	$5.93	1,408,940	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$4.09	03/05/2026		M			27,891	⁽¹⁾	12/10/2030	Common Stock	27,891	$0	0	D
Stock Option (Right to Buy)	$5.93	03/05/2026		M			14,036	⁽²⁾	01/31/2028	Common Stock	14,036	$0	0	D

Explanation of Responses:

1. The reporting person received the stock options on December 10, 2020 pursuant to an award under the Company's 2018 Stock Option/Stock Issuance Plan. 50% of the options vested on the first anniversary of the vesting commencement date, and the remaining 50% of options vested on the second anniversary of the vesting commencement date, in each case subject to continued employment through such vesting date.

2. The reporting person received the stock options on January 31, 2018 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date.

Remarks:

Chief Financial Officer

	/s/ Beth Hecht, Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Xeris Biopharma (XERS) report for Steven Pieper?

Xeris Biopharma reported that officer Steven Pieper exercised stock options to acquire common shares. On March 5, 2026, he converted previously granted options into 27,891 shares at $4.09 and 14,036 shares at $5.93, increasing his directly owned common stock.

How many Xeris Biopharma (XERS) shares does Steven Pieper hold after the Form 4?

After the reported option exercises, Steven Pieper directly owned up to 1,408,940 Xeris Biopharma common shares. This figure reflects sequential post-transaction ownership amounts disclosed for each exercise, showing his direct stake following the conversion of earlier stock option awards into common stock.

What stock option grants underlie Steven Pieper’s Xeris Biopharma (XERS) Form 4?

The Form 4 shows options originally granted on January 31, 2018 and December 10, 2020 under company stock option plans. Vesting occurred over time, with portions vesting on the first and second anniversaries or in monthly installments, conditioned on continued employment through each vesting date.

Were Steven Pieper’s Xeris Biopharma (XERS) transactions open-market buys or option exercises?

The transactions were option exercises, not open-market purchases. Each is coded “M” for exercise or conversion of derivative security, showing movement from stock options into common stock at specified per-share prices, consistent with exercising previously granted equity awards rather than buying in the market.